Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.4K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

324
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
324
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

14.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.1K
Introduction to Hemostasis01:05

Introduction to Hemostasis

15.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
15.4K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.0K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

423
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Movement behavior in adults with sickle cell disease compared to healthy adults: a cross-sectional study.

PloS one·2026
Same author

Early Detection of Post-Traumatic Heterotopic Ossification in Bleeding Disorders Using Ultrasound: A Multi-Center Case Series.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine·2025
Same author

Measuring Physical Function Capacity in Persons With Haemophilia: A Systematic Review of Performance-Based Methods.

Haemophilia : the official journal of the World Federation of Hemophilia·2025
Same author

Deep Learning Based Automatic Ankle Tenosynovitis Quantification from MRI in Patients with Psoriatic Arthritis: A Feasibility Study.

Diagnostics (Basel, Switzerland)·2025
Same author

DISH as a marker for incident diabetes mellitus in cardiovascular disease patients.

Rheumatology (Oxford, England)·2025
Same author

The Use of Primary Care Physiotherapy for Persons With Bleeding Disorders in the Netherlands-A Retrospective Study of Health Records.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Related Experiment Video

Updated: Mar 1, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.6K

Predicting Recovery After Joint Bleeding in Persons With Bleeding Disorders.

Gijs Aertssen1, Lize F D van Vulpen1, Wouter Foppen2

  • 1Center For Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|February 28, 2026
PubMed
Summary

Identifying predictors of joint bleed recovery in haemophilia is crucial. Patients with less range of motion limitation and those on emicizumab treatment experienced faster recovery times.

Keywords:
emicizumabhaemophiliahemarthrosisrecoverysurvival

More Related Videos

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine
08:27

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine

Published on: December 6, 2024

705
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Related Experiment Videos

Last Updated: Mar 1, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.6K
A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine
08:27

A New Hybrid Quantitative Evaluation Model for Axillary Junctional Hemorrhage in Swine

Published on: December 6, 2024

705
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Area of Science:

  • Hematology
  • Orthopedics
  • Pharmacology

Background:

  • Joint bleeds in haemophilia significantly impact patients' lives, with variable recovery times.
  • Predicting recovery is essential for personalized care, preventing long-term joint damage, and optimizing return to activities.

Purpose of the Study:

  • To identify key predictors of recovery duration following joint bleeds in individuals with haemophilia.

Main Methods:

  • Analysis of regular care data from haemophilia patients (2016-2025).
  • Primary outcome: time to normalization of clinical symptoms.
  • Statistical methods included Kaplan-Meier curves and Cox regression, examining variables like joint status, treatment, and emicizumab use.

Main Results:

  • Sixty-four joint bleeds in 44 patients were analyzed; 87.9% had haemophilia A.
  • Median recovery time was 32.5 days.
  • Absence of range of motion limitation predicted 2.3x faster recovery (p=0.007).
  • Emicizumab prophylaxis was associated with 2.7x faster recovery compared to factor-prophylaxis (p=0.027).

Conclusions:

  • Significant joint range of motion limitation at presentation prolongs recovery.
  • Emicizumab treatment in severe haemophilia A patients accelerates recovery post-joint bleed.
  • Personalized, extended follow-up beyond one month is recommended for optimal patient management.